Hepatocellular carcinoma (HCC) is the most
|
|
- Rudolf Lyons
- 5 years ago
- Views:
Transcription
1 Original Article / Biliary Hepatobiliary & Pancreatic Diseases International Prognosis of hepatocellular carcinoma with bile duct tumor thrombus after R0 resection: a matched study Ding-Ding Wang, Li-Qun Wu and Zu-Sen Wang Qingdao, China BACKGROUND: Hepatocellular carcinoma (HCC) with bile duct tumor thrombus (BDTT) is rare. The present study aimed to determine post-surgical prognoses in HCC patients with BDTT, as outcomes are currently unclear. METHODS: We compared the prognoses of 110 HCC patients without BDTT (group A) to 22 cases with BDTT (group B). The two groups were matched in age, gender, tumor etiology, size, number, portal vascular invasion, and TNM stage. Additionally, 28 HCC patients with BDTT were analyzed to identify prognostic risk factors. RESULTS: The 1-, 3-, and 5-year overall survival rates were 90.9%, 66.9%, and 55.9% for group A and 81.8%, 50.0%, and 37.5% for group B, respectively. The median survival time in groups A and B was 68.8 and 31.4 months, respectively (P=0.043). The patients for group B showed higher levels of serum total bilirubin, alanine aminotransferase and gammaglutamyl transferase, a larger hepatectomy range, and a higher rate of anatomical resection. In subgroup analyses of patients with BDTT who underwent R0 resection, TNM stage III- IV was an independent risk factor for overall survival; these patients had worse prognoses than those with TNM stage I-II after R0 resection (hazard ratio=6.056, P=0.014). Besides, univariate and multivariate analyses revealed that non-r0 resection and TNM stage III-IV were independent risk factors for both disease-free survival and overall survival of 28 HCC patients with BDTT. The median overall survival time of patients with BDTT who underwent R0 resection was longer than that of patients who did not undergo R0 resection (31.0 vs 4.0 months, P=0.007). Author Affiliations: Division of Hepatobiliary Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao , China (Wang DD, Wu LQ and Wang ZS) Corresponding Author: Li-Qun Wu, MD, PhD, Division of Hepatobiliary Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao , China (Tel: ; wulq5810@126.com) 2016, Hepatobiliary Pancreat Dis Int. All rights reserved. doi: /S (16) Published online September 29, CONCLUSIONS: R0 resection prolonged survival time in HCC patients with BDTT, although prognosis remains poor. For such patients, R0 resection is an important treatment that determines long-term survival. 626 Hepatobiliary Pancreat Dis Int,Vol 15,No 6 December 15, (Hepatobiliary Pancreat Dis Int 2016;15: ) KEY WORDS: hepatocellular carcinoma; bile duct tumor thrombus; prognosis; recurrence; R0 resection Introduction Hepatocellular carcinoma (HCC) is the most common type of liver cancer with a high mortality rate worldwide. Long-term prognosis is poor even among HCC patients who undergo radical surgery or liver transplantation. Liver tumor can invade the portal vein and bile duct, and cause vascular tumor thrombus or bile duct tumor thrombus (BDTT). Compared to the frequency of vascular invasion, HCC with BDTT is rare, with an incidence ranging from 0.5% to 12.9% according to autopsy and pathological specimens of HCCs. [1-5] Obstructive jaundice is a special symptom caused by bile duct invasion, which often results in misdiagnosis and poorer liver function. Despite the paucity of HCC with BDTT, several reports [6-12] showed that HCC with BDTT has a higher recurrence rate and poorer prognosis after surgery. However, the post-surgical prognosis remains controversial because of the absence of a unified treatment procedure. Surgical resection is the only radical cure for these patients. Moreover, there is little information about the prognosis of patients with BDTT after R0 resection in particular. This study aimed to identify the post-surgical prognosis, including the risk factors analysis, in HCC patients with BDTT. To that end, we analyzed the clinicopathological characteristics of HCC patients who received R0 and non-r0 resection at
2 R0 resection for HCC with BDTT our center, including patients with and without BDTT. We also discuss the optimal therapeutics for this type of HCC. Methods Patients and definitions Between January 1998 and December 2012, 1084 patients underwent surgery for HCC at the Division of Hepatobiliary Pancreatic Surgery, the Affiliated Hospital of Qingdao University. All surgical specimens were identified by pathological analysis, including 882 cases of R0 resection, 105 of R1 resection, and 97 of R2 resection; BDTT was found in 28 patients, 22 of them underwent R0 resection while 6 underwent R2 resection. The clinical and pathological specimens of these patients were retrospectively reviewed. In order to reduce the influence of non-radical resection, only patients who underwent R0 resection were selected. Propensity score matching was used to minimize selection bias and confounding factors. Group A included 110 patients chosen from 860 HCC patients without BDTT who underwent R0 resection. Group A patients were matched at a 5:1 ratio with 22 patients with BDTT according to age, gender, tumor etiology, tumor size, tumor number, portal vascular invasion, and American Joint Committee on Cancer (AJCC) TNM staging; these 22 patients comprised of group B. Additionally, the features of all 28 HCC patients with BDTT were analyzed to identify prognostic risk factors. This study was approved by the Ethics Committee of our hospital, and all patients or their guardians provided informed consent. The histological grade was evaluated in accordance with the standards of the Edmondson Steiner classification. The tumor stage was evaluated by operation and pathological analysis according to the 7th Edition of the AJCC Cancer Staging Manual. BDTT was divided into two types: microscopic BDTT, which can be observed beyond the second-order branch of the biliary tree, and macroscopic BDTT, which is restricted to the secondorder branch. [13] Liver function was assessed according to the Child-Pugh classification and the model for endstage liver disease (MELD) scoring system. Child-Pugh class A and a MELD score <8 were required for inclusion in the study, although some patients had Child-Pugh class B due to obstruction of the biliary tract. The liver residual volume was also required to be more than 50% of the total liver volume according to computed tomography (CT)-assisted three-dimensional reconstruction. Hepatectomies were classified into anatomical resection, en bloc resection of liver tumor according to the Couinaud segment, non-anatomical resection, partial resection, or tumor enucleation. The surgical procedure was determined on the basis of the liver function reserve, cirrhosis, and hepatectomy range of the patients. Hepatectomy was considered R0 resection when the bile duct and specimen margins were tumor-negative on histological and pathological analysis and the disease-free survival (DFS) time exceeded 2 months. Resection was considered R1 if the margin was histologically positive, and R2 if the margin was macroscopically positive. Follow-up Follow-up surveys were scheduled every month during the first 3 months post-surgery and every 3 months thereafter. Serum alpha-fetoprotein (AFP) assessments and abdominal ultrasonography (US) or chest and abdominal CT images were obtained at each follow-up. Patients with a surgical margin of <0.5 cm, multiple tumors, or vascular invasion were treated with preventive transcatheter arterial chemoembolization (TACE) at 3-4 weeks after surgery. All patients were followed-up until death or the study end date of December Statistical analysis All statistical analyses were performed using SPSS (version 13.0, SPSS Inc., Chicago, IL, USA). The Chi-square test was used to compare categorical variables. Continuous numerical variables were presented as mean ± standard deviation (SD) or median with interquartile range. The Kaplan-Meier method was used for survival analyses. Multivariate analysis was performed using the Cox multivariate regression model. A P value <0.05 was considered statistically significant. Results Patient profiles and pathological features Baseline information on the 28 HCC patients with BDTT is shown in Table 1. Among the 28 patients, 16 underwent choledochotomy and exploration, 11 underwent choledochotomy and embolectomy, and 1 underwent bile duct resection. The pathological features of the 28 HCC patients with BDTT are shown in Table 2. According to TNM staging, there were 15 stage I, 3 stage II, 9 stage III, and 1 stage IV. Sixteen cases were microscopic BDTT and 12 were macroscopic BDTT. Additionally, 5 cases had BDTT combined with bile duct wall invasion, which were proven by postoperative pathological analysis of surgical specimens, including 1 invasion to extrahepatic bile duct wall. Prognosis of HCC patients with BDTT after R0 resection The characteristics of groups A and B were compared Hepatobiliary Pancreat Dis Int,Vol 15,No 6 December 15,
3 Hepatobiliary & Pancreatic Diseases International and analyzed in Table 3. There were no significant intergroup differences in age, gender, cirrhosis, portal hypertension, preoperative TACE, surgical margin, amount of bleeding, blood transfusion, serum AFP level, tumor size, tumor number, portal vascular invasion, TNM stage, or differentiation status between the two groups. Levels of serum total bilirubin, serum alanine aminotransferase (ALT), and serum gamma-glutamyl transferase (GGT) were higher in patients in group B. These patients also showed a larger hepatectomy range and higher rate of anatomical resection. Fourteen patients from group B had recurrence; 7 Table 1. Preoperative demographic and clinical features of patients with HCC and BDTT (n, %) Values Age (yr) 54.8±11.3 Gender (male/female) 22/6 Primary background liver status HBsAg 23 (82.1) Anti-HCV 0 Non-viral liver disease 5 (17.9) Child-Pugh classification Class A 16 (57.1) Class B 12 (42.9) Total bilirubin (µmol/l) 34.6 ( ) ALT level (U/L) 69 (14-481) AFP (ng/ml) > (39.3) (60.7) Preoperative HCC treatment None 25 (89.3) TACE 3 (10.7) Hepatectomy range 1 4 (14.3) 2 9 (32.1) 3 15 (53.6) Surgical margin (mm) <5 18 (64.3) 5 10 (35.7) Hepatic vascular occlusion Yes 18 (64.3) No 10 (35.7) Bleeding (ml) < (71.4) (28.6) Blood transfusion Yes 15 (53.6) No 13 (46.4) Anatomical resection Yes 14 (50.0) No 14 (50.0) R0 resection Yes 22 (78.6) No 6 (21.4) Table 2. Pathological findings of patients with HCC and BDTT (n, %) Values Background liver status Normal or chronic hepatitis 4 (14.3) Cirrhosis 24 (85.7) Tumor number 1 20 (71.4) 2 3 (10.7) 3 5 (17.9) Maximal tumor size (cm) 6.8±3.5 Portal vascular invasion Yes 18 (64.3) No 10 (35.7) Histologic differentiation Well 1 (3.6) Moderate 15 (53.5) Poor 12 (42.9) TNM staging I 15 (53.6) II 3 (10.7) III 9 (32.1) IV 1 (3.6) Bile duct thrombus type Microscopic 16 (57.1) Macroscopic 12 (42.9) Bile duct wall invasion Yes 5 (17.9) No 23 (82.1) Table 3. Comparison of clinicopathological features between groups A and B Group A (n=110) Group B (n=22) P value Age ( 65/>65 yr) 86/24 20/ Gender (male/female) 90/20 18/ Child-Pugh classification (A/B) 105/5 21/ Cirrhosis 88/22 18/ Portal hypertension 14/96 3/ Total bilirubin ( 17.1/>17.1 µmol/l) 74/36 6/ ALT ( 50/>50 U/L) 80/30 10/ GGT ( 64/>64 U/L) 72/38 2/ Preoperative TACE 20/90 2/ Hepatectomy range >3 23/87 11/ Anatomical resection 37/73 14/ Surgical margin (<0.5/ 0.5 cm) 71/39 17/ Blood transfusion 36/74 12/ Bleeding 1000 ml 13/97 5/ AFP ( 400/>400 ng/ml) 74/36 12/ Multiple tumor 18/92 4/ Tumor size ( 5.0/>5.0 cm) 51/59 8/ Portal vascular invasion 21/89 5/ TNM stage (I-II/ III-IV) 78/32 16/ Differentiation (well/poor) 75/35 13/ Hepatobiliary Pancreat Dis Int,Vol 15,No 6 December 15,2016
4 R0 resection for HCC with BDTT were within 1 year. The median survival time was significantly different between the two groups after R0 resection (68.8 vs 31.4 months for group A vs B, respectively, P=0.043) (Fig. 1). The 1-, 3-, and 5-year overall survival (OS) rates were 90.9%, 66.9%, and 55.9% for group A and 81.8%, 50.0%, and 37.5% for group B, respectively. Subgroup analysis of R0 resection In subgroup analysis of group B, univariate and multivariate analyses revealed that TNM stage III-IV was an independent risk factor for OS of R0 resection patients (Table 4). However, these analyses did not reveal any risk factors for DFS in the R0 resection group. The median survival time of the TNM stage I-II group was longer than that of the TNM stage III-IV group after R0 resection (31.4 vs 10.0 months, P=0.031). The 22 patients with BDTT had a 5-year OS rate of 37.5%; of those, the 16 patients with TNM stage I-II had a 5-year OS rate of 46.9%. Survival analysis of 28 HCC patients with BDTT The 1-, 3-, and 5-year OS rates were 90.9%, 39.3%, and 29.9% for 28 HCC patients with BDTT. We performed univariate Kaplan-Meier analysis to identify the factors influencing the prognosis of 28 HCC patients with BDTT (Table 5). Cox multivariate regression analysis was also performed on factors with P<0.10 on univariate analysis for both DFS and OS (Table 6). The analyses Fig. 1. Comparison of survival time curves between groups A and B after R0 resection (P=0.043). Table 4. Univariate and multivariate analysis of risk factors for overall survival of R0 resection patients Univariate analysis Median (mon) Age ( 65/>65 yr) 61.0/ Gender (male/female) 31.4/ Cirrhosis 31.0/ Portal hypertension 31.0/ BDTT type (micro/macro) 21.0/ TNM stage (I-II/ III-IV) Tumor size ( 5.0/>5.0 cm) Surgical margin (<0.5/ 0.5 cm) Blood transfusion Bleeding 1000 ml Hepatectomy range >3 Anatomical resection Multivariate analysis P value HR 95% CI P value 31.4/ / / / / / / HR: hazard risk; CI: confidence interval. Table 5. Univariate analysis of risk factors for patient survival and recurrence DFS Median (mon) OS P value Median (mon) P value Age ( 65/>65 yr) 25.0/ / Gender (male/female) 15.0/ / Cirrhosis 9.9/ / Portal hypertension 7.0/ / Differentiation (well/poor) 25.0/ / BDTT type (micro/macro) 8.0/ / AFP ( 400/>400 ng/ml) 25.4/ / TNM stage (I-II/III-IV) 25.4/ / Multiple tumor 9.9/ / Portal vascular invasion 13.0/ / Tumor size ( 5.0/>5.0 cm) 37.8/ / Surgical margin (<0.5/ 0.5 cm) 7.0/ / Blood transfusion 15.0/ / Bleeding 1000 ml 13.0/ / Hepatectomy range >3 7.0/ / Anatomical resection 50.2/ / R0 resection 25.0/ / DFS: disease-free survival; OS: overall survival. Table 6. Multivariate analysis of risk factors for patient survival and recurrence HR 95% CI P value Disease-free survival TNM stage (III-IV) Non-R0 resection Overall survival TNM stage (III-IV) Non-R0 resection HR: hazard risk; CI: confidence interval. Hepatobiliary Pancreat Dis Int,Vol 15,No 6 December 15,
5 Hepatobiliary & Pancreatic Diseases International Fig. 2. Comparison of survival time of HCC patients with BDTT treated with invasive procedures and those treated conservatively after recurrence (P=0.002). revealed that non-r0 resection and TNM stage III-IV were independent risk factors of DFS and OS for HCC patients with BDTT. Additionally, the median overall survival time of patients with BDTT who underwent R0 resection was longer than that of patients who underwent non-r0 resection (31.0 vs 4.0 months, P=0.007). Treatment for tumor recurrence Of the 28 HCC patients with BDTT, 20 (71.4%) experienced intrahepatic recurrence after surgery, including 4 (20.0%) BDTT recurrences (within 1 year) and 2 (10.0%) who also had extrahepatic recurrence. Among patients with recurrence, 13 (65.0%) underwent active treatment, including TACE (n=8), percutaneous transhepatic cholangiography (n=2), endoscopic biliary metal stent drainage (n=2), and radiofrequency ablation (n=1). The remaining 7 patients with recurrence underwent conservative treatment alone because of poor liver function or for other reasons. Notably, 4 patients with BDTT recurrence exhibited macroscopic BDTT, and this difference was significant (likelihood ratio test, odds ratio=6.556, P=0.010). The DFS of each of these 4 patients, who underwent choledochotomy, was 3.0, 6.2, 7.0, and 9.9 months, respectively. The median survival time after recurrence of patients with active treatment was 9.2 months, which was longer than that of patients with conservative treatment (3.0 months; P=0.002) (Fig. 2). Discussion The incidence of HCC with BDTT in this study was 2.58% (28/1084), which is within the 0.5% to 12.9% range reported previously. [1-5] However, studies have not conclusively shown whether HCC patients with BDTT have a poorer long-term prognosis after surgery. Shiomi et al [1] reported that there are no significant differences in prognosis between patients with and without BDTT after appropriate preoperative management. Likewise, Satoh et al [9] showed that the prognosis of HCC patients with BDTT is similar to that of patients without BDTT. However, Ikenaga et al [6] reported that HCC with BDTT has a poorer prognosis than HCC without BDTT after resection. Yeh et al [8] found that HCC patients with BDTT have significantly worse OS than those without BDTT, especially those with concomitant vascular invasion. Noda et al [12] also found that HCC patients with BDTT have lower OS rates compared to those without BDTT, and that patients with BDTT have a lower curative resection rate. Previous studies [6-12] have only selected patients who underwent hepatectomy, but did not distinguish between curative or non-curative resection. Therefore, we only chose patients who underwent R0 resection to avoid the influence of non-curative resection on our analysis. The median survival time for patients with BDTT was still significantly shorter than that for patients without BDTT after R0 resection which implied that patients with BDTT have worse prognoses even after R0 resection. Peng et al [14] reported that the poor prognosis of HCC patients with BDTT is attributed to low resectability and poor liver function. In our study, tumor progression and portal vascular invasion were matched between patients with or without BDTT. The preoperative levels of serum total bilirubin, ALT, and GGT were higher in patients with BDTT; this indicates poor liver function owing to bile duct obstruction. Obstructive jaundice occurred in up to 12 patients with BDTT diagnosed by preoperative laboratory examination. Meanwhile, the larger hepatectomy range and higher rate of anatomical resection were due to tumor invasion of the bile duct, which necessitates anatomical resection of this part of the Glisson s sheath in order to reduce the residual tumor. Additionally, Shao et al [7] and Zeng et al [3] reported that 25.9% and 52.3% of patients with BDTT, respectively, showed BDTT recurrence after surgery, and speculated that bile duct invasion might be another route of intrahepatic metastasis that causes BDTT recurrence. In the current study, 4 patients experienced early local BDTT recurrence (<1 year). Although the tumor thrombus easily separated from the bile duct during surgery, we speculated that BDTT recurrence in these patients was due to the duct wall invasion of the tumor thrombus. Compared to patients with microscopic BDTT, those with macroscopic BDTT exhibit a higher possibility of bile duct wall invasion. Therefore, bile duct invasion may be a route of metastasis that leads to early local recurrence and poor prognosis in HCC patients with BDTT. These findings indicate that HCC with BDTT can result 630 Hepatobiliary Pancreat Dis Int,Vol 15,No 6 December 15,2016
6 R0 resection for HCC with BDTT in worse prognosis for poor liver function and potential metastasis through the bile duct even after R0 resection, and that such cases should receive more attention. Notably, BDTT is considered in the Japanese TNM staging system; however, intrahepatic bile duct invasion is no longer included in the chapter on HCC staging in the 7th Edition of the AJCC Cancer Staging Manual. Minagawa et al [15] showed that the prognostic stratification ability of the Japanese TNM staging system is more effective than that of the AJCC TNM staging system. According to the 7th Edition of the AJCC Cancer Staging Manual, TNM staging of HCC considers most tumor characteristics, including tumor size, number, vascular invasion, lymph node involvement, and distant metastasis; hence, TNM stage is greatly relevant to tumor prognosis. Notably, we found that TNM stage III-IV was the only independent risk factor for OS in this subgroup. The 22 patients with BDTT who underwent R0 resection had a 5-year OS rate of 37.5%; of those, the 16 patients with TNM stage I-II had a 5-year OS rate of 46.9%. Moon et al [16] and Zeng et al [3] found that surgical curability is an independent risk factor for both OS and DFS in HCC patients with BDTT. In our study, non-r0 resection and TNM stage III-IV were independent risk factors for tumor recurrence and prognosis in 28 HCC patients with BDTT. Although patients with BDTT have a poor prognosis and low curative resection rate, R0 resection is still an important treatment for improving long-term prognosis, and can significantly reduce recurrence in patients with BDTT. Meanwhile, patients with recurrence who obtained active treatment had longer OS than patients who received conservative management. Peng et al [14] also reported that repeated surgery resulted in longer survival for HCC patients with BDTT. Therefore, in addition to tumor progression, the prognosis of HCC patients with BDTT can be estimated by R0 resection, which yields a satisfactory outcome. Patients with TNM stage III-IV should undergo frequent follow-up checks after R0 resection. Although en bloc resection of the primary tumor with choledochotomy and embolectomy is considered an effective technique for curative resection of HCC with BDTT, this approach remains controversial. Shiomi et al [1] and Satoh et al [9] reported that hepatectomy with choledochotomy and embolectomy was as effective as bile duct resection, and that there were no differences in OS between patients who underwent choledochotomy and those who underwent bile duct resection. However, [17, 18] other studies reported that tumor embolectomy through a choledochotomy might cause intraoperative iatrogenic implantation and thereby cause tumor recurrence. In this study, 16 patients underwent choledochotomy and exploration, 11 patients underwent choledochotomy and embolectomy, and only 1 patient underwent bile duct resection for macroscopic bile duct wall invasion; this yielded a favorable 5-year OS rate of 29.9%. It is generally accepted that most of the BDTT can be easily separated from the bile duct because BDTT rarely invades the bile duct walls and usually only loosely attaches to the epithelium. [14] In our series, BDTT was easily separated in most cases, and only 1 patient underwent bile duct resection because a tumor thrombus was tightly lodged in the bile duct. However, 2 of the 27 patients who underwent choledochotomy and embolectomy experienced bile duct bleeding after embolectomy; both belonged to the R2 resection group, and the DFS was 1 and 2 months, respectively. Bile duct bleeding might have been due to BDTT invasion of the bile duct walls, or to the entry of the tumor into the bile duct after embolectomy, both of which might have caused early recurrence because of residual tumor in the bile duct wall. Furthermore, we speculate that the BDTT recurrence in 4 patients was due to duct wall invasion by the tumor thrombus. Zeng et al [3] reported that 66.7% of macroscopic BDTT-proven patients exhibited bile duct wall invasion according to postoperative or intraoperative pathological findings. In our study, 5 patients had proven bile duct thrombi combined with bile duct wall invasion on postoperative pathology. Therefore, bile duct resection might be necessary to reduce the recurrence rates in patients with HCC who have macroscopic BDTT and who are suspected of having bile duct wall invasion. Unfortunately, the diagnosis of bile duct wall invasion is difficult, whether by macroscopic testing during surgery or imaging prior to surgery. Therefore, we deduce that hepatectomy with choledochotomy for patients with microscopic BDTT ought to be recommended; bile duct resection is necessary to achieve R0 resection and to reduce the possibility of recurrence for patients with macroscopic BDTT suspected to have, or diagnosed with, bile duct wall invasion. This is especially true for those with bile duct bleeding after embolectomy or those with invasion confirmed by pathology. However, further direct evidence of this approach will be necessary before drawing a definitive conclusion. There are several limitations of this study. First, the number of patients is small. Second, the fact that this is a single-center study may have introduced bias. Additional clinical retrospective and prospective studies are required to confirm these results. Furthermore, the pathogenesis of BDTT in HCC patients requires further research. In conclusion, R0 resection is an important treatment for the long-term survival of HCC patients with BDTT, although the prognosis remains poor. However, Hepatobiliary Pancreat Dis Int,Vol 15,No 6 December 15,
7 Hepatobiliary & Pancreatic Diseases International further studies with a greater number of subjects are necessary to verify these conclusions. Contributors: WLQ proposed the study. WDD and WZS performed the research and wrote the first draft. WDD collected and analyzed the data. All authors contributed to the design and interpretation of the study and to further drafts. WLQ is the guarantor. Funding: None. Ethical approval: This study was approved by the Ethics Committee of the Affiliated Hospital of Qingdao University. Competing interest: The authors do not choose to declare any conflict of interest related directly or indirectly to the subject of this article. References 1 Shiomi M, Kamiya J, Nagino M, Uesaka K, Sano T, Hayakawa N, et al. Hepatocellular carcinoma with biliary tumor thrombi: aggressive operative approach after appropriate preoperative management. Surgery 2001;129: Ueda M, Takeuchi T, Takayasu T, Takahashi K, Okamoto S, Tanaka A, et al. Classification and surgical treatment of hepatocellular carcinoma (HCC) with bile duct thrombi. Hepatogastroenterology 1994;41: Zeng H, Xu LB, Wen JM, Zhang R, Zhu MS, Shi XD, et al. Hepatocellular carcinoma with bile duct tumor thrombus: a clinicopathological analysis of factors predictive of recurrence and outcome after surgery. Medicine (Baltimore) 2015;94:e Huang JF, Wang LY, Lin ZY, Chen SC, Hsieh MY, Chuang WL, et al. Incidence and clinical outcome of icteric type hepatocellular carcinoma. J Gastroenterol Hepatol 2002;17: Qin LX, Ma ZC, Wu ZQ, Fan J, Zhou XD, Sun HC, et al. Diagnosis and surgical treatments of hepatocellular carcinoma with tumor thrombosis in bile duct: experience of 34 patients. World J Gastroenterol 2004;10: Ikenaga N, Chijiiwa K, Otani K, Ohuchida J, Uchiyama S, Kondo K. Clinicopathologic characteristics of hepatocellular carcinoma with bile duct invasion. J Gastrointest Surg 2009;13: Shao W, Sui C, Liu Z, Yang J, Zhou Y. Surgical outcome of hepatocellular carcinoma patients with biliary tumor thrombi. World J Surg Oncol 2011;9:2. 8 Yeh CN, Jan YY, Lee WC, Chen MF. Hepatic resection for hepatocellular carcinoma with obstructive jaundice due to biliary tumor thrombi. World J Surg 2004;28: Satoh S, Ikai I, Honda G, Okabe H, Takeyama O, Yamamoto Y, et al. Clinicopathologic evaluation of hepatocellular carcinoma with bile duct thrombi. Surgery 2000;128: Yu XH, Xu LB, Liu C, Zhang R, Wang J. Clinicopathological characteristics of 20 cases of hepatocellular carcinoma with bile duct tumor thrombi. Dig Dis Sci 2011;56: Kim JM, Kwon CH, Joh JW, Sinn DH, Park JB, Lee JH, et al. Incidental microscopic bile duct tumor thrombi in hepatocellular carcinoma after curative hepatectomy: a matched study. Medicine (Baltimore) 2015;94:e Noda T, Nagano H, Tomimaru Y, Murakami M, Wada H, Kobayashi S, et al. Prognosis of hepatocellular carcinoma with biliary tumor thrombi after liver surgery. Surgery 2011;149: Esaki M, Shimada K, Sano T, Sakamoto Y, Kosuge T, Ojima H. Surgical results for hepatocellular carcinoma with bile duct invasion: a clinicopathologic comparison between macroscopic and microscopic tumor thrombus. J Surg Oncol 2005;90: Peng SY, Wang JW, Liu YB, Cai XJ, Deng GL, Xu B, et al. Surgical intervention for obstructive jaundice due to biliary tumor thrombus in hepatocellular carcinoma. World J Surg 2004;28: Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of patients in Japan. Ann Surg 2007;245: Moon DB, Hwang S, Wang HJ, Yun SS, Kim KS, Lee YJ, et al. Surgical outcomes of hepatocellular carcinoma with bile duct tumor thrombus: a Korean multicenter study. World J Surg 2013;37: Mok KT, Chang HT, Liu SI, Jou NW, Tsai CC, Wang BW. Surgical treatment of hepatocellular carcinoma with biliary tumor thrombi. Int Surg 1996;81: Wang HJ, Kim JH, Kim JH, Kim WH, Kim MW. Hepatocellular carcinoma with tumor thrombi in the bile duct. Hepatogastroenterology 1999;46: Received October 13, 2015 Accepted after revision May 20, Hepatobiliary Pancreat Dis Int,Vol 15,No 6 December 15,2016
Bile duct invasion can be an independent prognostic factor in early stage hepatocellular carcinoma
Korean J Hepatobiliary Pancreat Surg 2015;19:167-172 http://dx.doi.org/10.14701/kjhbps.2015.19.4.167 Original Article Bile duct invasion can be an independent prognostic factor in early stage hepatocellular
More informationClinical Study Clinical Characteristics and Surgical Prognosis of Hepatocellular Carcinoma with Bile Duct Invasion
Gastroenterology Research and Practice, Article ID 604971, 7 pages http://dx.doi.org/10.1155/2014/604971 Clinical Study Clinical Characteristics and Surgical Prognosis of Hepatocellular Carcinoma with
More informationUsefulness of Resection for Hepatocellular Carcinoma with Macroscopic Bile Duct Tumor Thrombus
Usefulness of Resection for Hepatocellular Carcinoma with Macroscopic Bile Duct Tumor Thrombus ATSUSHI OBA 1, SHINICHIRO TAKAHASHI 1, YUICHIRO KATO 1, NAOTO GOTOHDA 1, TAKAHIRO KINOSHITA 1, HIDEHITO SHIBASAKI
More informationCelsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging
Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery
More informationNegative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma
Li et al. World Journal of Surgical Oncology (2015) 13:294 DOI 10.1186/s12957-015-0713-4 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Negative impact of low body mass index on liver cirrhosis
More informationPreoperative Albumin-Bilirubin Score for Postoperative Solitary Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh A Cirrhosis
3862 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(18): 3862-3867. doi: 10.7150/jca.21313 Preoperative Albumin-Bilirubin Score for Postoperative Solitary Hepatocellular Carcinoma
More informationEffectiveness of additional resection of the invasive cancer-positive proximal bile duct margin in cases of hilar cholangiocarcinoma
Original Article Effectiveness of additional resection of the invasive cancer-positive proximal bile duct margin in cases of hilar cholangiocarcinoma Wen-Jie Ma 1#, Zhen-Ru Wu 2#, Anuj Shrestha 1,3, Qin
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationOriginal Article Relationship of different surgical margins with recurrence-free survival in patients with hepatocellular carcinoma
Int J Clin Exp Pathol 2015;8(3):3404-3409 www.ijcep.com /ISSN:1936-2625/IJCEP0004822 Original Article Relationship of different surgical margins with recurrence-free survival in patients with hepatocellular
More informationPrognostic importance of bile duct invasion in surgical resection with curative intent for hepatocellular carcinoma using PSM analysis
ONCOLOGY LETTERS 16: 3593-3602, 2018 Prognostic importance of bile duct invasion in surgical resection with curative intent for hepatocellular carcinoma using PSM analysis XINWEI YANG 1*, ZHIQUAN QIU 1*,
More informationClinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion
pissn 2287-2728 eissn 2287-285X Original Article Clinical and Molecular Hepatology 2017;23:160-169 Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion
More informationTitle:Identification of a novel microrna signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis
Author's response to reviews Title:Identification of a novel microrna signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis Authors: Mei-Yin Zhang (zhangmy@sysucc.org.cn) Shu-Hong
More informationRESEARCH ARTICLE. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment
DOI:10.22034/APJCP.2017.18.6.1697 RESEARCH ARTICLE Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment Alan Chuncharunee 1,
More informationIs Hepatic Resection Needed in the Patients with Peritoneal Side T2 Gallbladder Cancer?
Is Hepatic Resection Needed in the Patients with Peritoneal Side T2 Gallbladder Cancer? Lee H, Park JY, Youn S, Kwon W, Heo JS, Choi SH, Choi DW Department of Surgery, Samsung Medical Center Sungkyunkwan
More informationAlthough hepatocellular carcinoma (HCC) with lymph node
ORIGINAL ARTICLE Impact of Histologically Confirmed Lymph Node Metastases on Patient Survival After Surgical Resection for Hepatocellular Carcinoma Report of a Japanese Nationwide Survey Kiyoshi Hasegawa,
More informationPreoperative Biliary Drainage Among Patients With Resectable Hepatobiliary Malignancy: Does Technique Matter?
Preoperative Biliary Drainage Among Patients With Resectable Hepatobiliary Malignancy: Does Technique Matter? Q. Lina Hu, MD; Jason B. Liu, MD, MS; Ryan J. Ellis, MD, MS; Jessica Y. Liu, MD, MS; Anthony
More informationSatisfactory surgical outcome of T2 gastric cancer after modified D2 lymphadenectomy
Original Article Satisfactory surgical outcome of T2 gastric cancer after modified D2 lymphadenectomy Shupeng Zhang 1, Liangliang Wu 2, Xiaona Wang 2, Xuewei Ding 2, Han Liang 2 1 Department of General
More informationEffect of hepatitis B virus DNA replication level and anti-hbv therapy on microvascular invasion of hepatocellular carcinoma
Qu et al. Infectious Agents and Cancer (2019) 14:2 https://doi.org/10.1186/s13027-019-0219-8 RESEARCH ARTICLE Open Access Effect of hepatitis B virus DNA replication level and anti-hbv therapy on microvascular
More informationHepatic resection is a well-accepted therapy for hepatocellular
ORIGINAL ARTICLES Early and Late After Liver Resection for Hepatocellular Carcinoma Prognostic and Therapeutic Implications Nazario Portolani, MD,* Arianna Coniglio, MD,* Sara Ghidoni, MD,* Mara Giovanelli,
More informationChronic infections with hepatitis B and hepatitis C
Original Article / Liver The impact of family history of hepatocellular carcinoma on its patients' survival Wing Chiu Dai, Sheung Tat Fan, Tan To Cheung, Kenneth SH Chok, Albert CY Chan, Simon HY Tsang,
More informationXiang Hu*, Liang Cao*, Yi Yu. Introduction
Original Article Prognostic prediction in gastric cancer patients without serosal invasion: comparative study between UICC 7 th edition and JCGS 13 th edition N-classification systems Xiang Hu*, Liang
More informationPrognostic factors after hepatic resection for the single hepatocellular carcinoma larger than 5 cm
ORIGINAL ARTICLE pissn 2288-6575 eissn 2288-6796 http://dx.doi.org/1174/astr.216.91.3.14 Annals of Surgical Treatment and Research Prognostic factors after hepatic resection for the single hepatocellular
More informationpitfall Table 1 4 disorientation pitfall pitfall Table 1 Tel:
11 687 692 2002 pitfall 1078 29 17 9 1 2 3 dislocation outflow block 11 1 2 3 9 1 2 3 4 disorientation pitfall 11 687 692 2002 Tel: 075-751-3606 606-8507 54 2001 8 27 2002 10 31 29 4 pitfall 16 1078 Table
More informationRui-qing Liu 1,2, Shu-jing Shen 1, Xiu-feng Hu 3, Jie Liu 3, Li-juan Chen 3 and Xing-ya Li 1*
Liu et al. Cancer Cell International 2013, 13:99 PRIMARY RESEARCH Open Access Prognosis of the intrahepatic cholangiocarcinoma after resection: hepatitis B virus infection and adjuvant chemotherapy are
More informationNatural History and Treatment Trends in Hepatocellular Carcinoma Subtypes: Insights From a National Cancer Registry
2015;112:872 876 Natural History and Treatment Trends in Hepatocellular Carcinoma Subtypes: Insights From a National Cancer Registry PETER L. JERNIGAN, MD, KOFFI WIMA, MS, DENNIS J. HANSEMAN, PhD, RICHARD
More informationORIGINAL ARTICLE. Jun Zheng 1, Rong-chun Xing 1, Wei-hong Zheng 2, Wei Liu 1, Ru-cheng Yao 1, Xiao-song Li 1, Jian-ping Du 1, Lin Li 1.
JBUON 2017; 22(3): 709-713 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE A comparative study on postoperative mortality prediction of SFLI scoring
More informationIntrahepatic cholangiocarcinoma: the AJCC/UICC 8 th edition updates
Review Article Page 1 of 5 Intrahepatic cholangiocarcinoma: the AJCC/UICC 8 th edition updates Andrew J. Lee, Yun Shin Chun Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center,
More informationSi Hyun Bae, 1,2,3 Do Seon Song, 1,2,3 Myeong Jun Song, 1,4 Woo Jin Chung, 1,5
Comparison of efficacy between hepatic arterial infusion chemotherapy and sorafenib in advanced hepatocellular carcinoma with portal vein tumor thrombosis 1,2,3 Si Hyun Bae, 1,2,3 Do Seon Song, 1,2,3 Myeong
More informationSignificance of the lymph nodes in the 7th station in rational dissection for metastasis of distal gastric cancer with different T categories
Original Article Significance of the lymph nodes in the 7th station in rational dissection for metastasis of distal gastric cancer with different T categories Wu Song, Yulong He, Shaochuan Wang, Weiling
More informationHepatocellular Carcinoma Surveillance
Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1 Patient Case 69 year-old otherwise healthy male with compensated
More informationEmbolotherapy for Cholangiocarcinoma: 2016 Update
Embolotherapy for Cholangiocarcinoma: 2016 Update Igor Lobko,MD Chief, Division Vascular and Interventional Radiology Long Island Jewish Medical Center GEST 2016 Igor Lobko, M.D. No relevant financial
More informationManagement of hepatocellular carcinoma should consider both tumor factors and background liver factors
Hepatocellular Carcinoma Column: Editorial Management of hepatocellular carcinoma should consider both tumor factors and background liver factors Shuji Nomoto, Mitsuhiro Hishida, Yoshikuni Inokawa, Hiroyuki
More informationHow to apply HCC prediction models to practice?
How to apply HCC prediction models to practice? Department of Internal Medicine, Keimyung University School of Medicine Woo Jin Chung HCC prediction models 독특하게간세포암환자들의생존은암의진행상태뿐아니라기저간기능의중증정도에영향을받는특성이있다.
More informationMultiple Primary Quiz
Multiple Primary Quiz Case 1 A 72 year old man was found to have a 12 mm solid lesion in the pancreatic tail by computed tomography carried out during a routine follow up study of this patient with adult
More informationGang Huang, MD; Wan Yee Lau, MD, FRCS; Wei-ping Zhou, MD, PhD; Feng Shen, MD, PhD; Ze-ya Pan, MD; Sheng-xian Yuan, MD; Meng-chao Wu, MD
Research Original Investigation Prediction of Hepatocellular Carcinoma Recurrence in Patients With Low Hepatitis B Virus DNA Levels and High Preoperative Hepatitis B Surface Antigen Levels Gang Huang,
More informationOver the past 20 years, great progress has been made in the
ORIGINAL ARTICLES Staging of Hepatocellular Carcinoma Assessment of the Japanese TNM and AJCC/UICC TNM Systems in a Cohort of 13,772 Patients in Japan Masami Minagawa, MD, PhD,* Iwao Ikai, MD, PhD,* Yutaka
More informationPeri-Transplant Change in AFP Level: A Useful Predictor of Hepatocellular Carcinoma Recurrence Following Liver Transplantation
ORIGINAL ARTICLE Cell Therapy & Organ Transplantation http://dx.doi.org/1.3346/jkms.16.31.7.149 J Korean Med Sci 16; 31: 149-154 Peri-Transplant Change in AFP Level: A Useful Predictor of Hepatocellular
More informationNomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma
doi: 10.2169/internalmedicine.9064-17 Intern Med Advance Publication http://internmed.jp ORIGINAL ARTICLE Nomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation
More informationAddictive Benefit of Transarterial Chemoembolization and Sorafenib in Treating Advanced Stage Hepatocelluar Carcinoma: Propensity Analysis
Addictive Benefit of Transarterial Chemoembolization and Sorafenib in Treating Advanced Stage Hepatocelluar Carcinoma: Propensity Analysis Gwang Hyeon Choi, Ju Hyun Shim*, Min-Joo Kim, Min-Hee Ryu, Baek-Yeol
More informationExtended multi-organ resection for ct4 gastric carcinoma: A retrospective analysis
Original Article Extended multi-organ resection for ct4 gastric carcinoma: A retrospective analysis 1. Longbin Xiao, 2. Mingzhe Li, 3. Fengfeng Xu, Department of General Surgery I, 4. Huishao Ye, Department
More informationRisk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma
720863TUB0010.1177/1010428317720863Tumor BiologyHong et al. research-article20172017 Original Article Risk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma Tumor Biology
More informationSupplementary Information
Supplementary Information Prognostic Impact of Signet Ring Cell Type in Node Negative Gastric Cancer Pengfei Kong1,4,Ruiyan Wu1,Chenlu Yang1,3,Jianjun Liu1,2,Shangxiang Chen1,2, Xuechao Liu1,2, Minting
More informationA study on clinicopathological features and prognostic factors of patients with upper gastric cancer and middle and lower gastric cancer.
Biomedical Research 2018; 29 (2): 365-370 ISSN 0970-938X www.biomedres.info A study on clinicopathological features and prognostic factors of patients with upper gastric cancer and middle and lower gastric
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationMedicine. Infiltrative Hepatocellular Carcinoma. Assessment of Factors Associated With Outcomes in Patients Undergoing Hepatectomy
Medicine OBSERVATIONAL STUDY Infiltrative Hepatocellular Carcinoma Assessment of Factors Associated With Outcomes in Patients Undergoing Hepatectomy Xiaopeng Yan, MD, Xu Fu, MD, Min Deng, MM, Jun Chen,
More informationRadiation Therapy for Liver Malignancies
Outline Radiation Therapy for Liver Malignancies Albert J. Chang, M.D., Ph.D. Department of Radiation Oncology, UCSF March 23, 2014 Rationale for developing liver directed therapies Liver directed therapies
More information290 Clin Oncol Cancer Res (2009) 6: DOI /s
290 Clin Oncol Cancer Res (2009) 6: 290-295 DOI 10.1007/s11805-009-0290-9 Analysis of Prognostic Factors of Esophageal and Gastric Cardiac Carcinoma Patients after Radical Surgery Using Cox Proportional
More informationRESEARCH ARTICLE. Qian Liu, Jian-Jun Bi, Yan-Tao Tian, Qiang Feng, Zhao-Xu Zheng, Zheng Wang* Abstract. Introduction. Materials and Methods
RESEARCH ARTICLE Outcome after Simultaneous Resection of Gastric Primary Tumour and Synchronous Liver Metastases: Survival Analysis of a Single-center Experience in China Qian Liu, Jian-Jun Bi, Yan-Tao
More informationSurgical management of HCC. Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London
Surgical management of HCC Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London Global distribution of HCC and staging systems WEST 1. Italy (Milan,
More informationORIGINAL ARTICLE. Summary. Introduction
JBUON 2017; 22(4): 936-941 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE A propensity score-matched case-control comparative study of laparoscopic
More informationSEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA
SEQUENCING OF HCC TREATMENT Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA February 2018 DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationUse of hepatic blood inflow occlusion and hemihepatic artery retention in liver resection for hepatocellular carcinoma
Original Article Use of hepatic blood inflow occlusion and hemihepatic artery retention in liver resection for hepatocellular carcinoma Changjun Jia, Chaoliu Dai, Xingyu Zhao, Xianmin Bu, Feng Xu, Songlin
More informationExpression of lncrna TCONS_ in hepatocellular carcinoma and its influence on prognosis and survival
European Review for Medical and Pharmacological Sciences 2017; 21: 5655-5660 Expression of lncrna TCONS_00027978 in hepatocellular carcinoma and its influence on prognosis and survival Q. CHEN 1, G.-D.
More informationPEER-REVIEW REPORT CLASSIFICATION LANGUAGE EVALUATION SCIENTIFIC MISCONDUCT CONCLUSION. [ Y] Accept [ ] Grade B: Very good
Reviewer s code: 03656588 Reviewer s country: China Date reviewed: 2017-06-08 [ ] Grade A: Excellent [ Y] Accept [ ] Grade B: Very good [ ] High priority for [ Y] Grade C: Good language [ ] Major revision
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationCurrent status of hepatic surgery in Korea
Korean J Hepatol. 2009 Dec; 15(Suppl 6):S60 - S64. DOI: 10.3350/kjhep.2009.15.S6.S60 Current status of hepatic surgery in Korea Kyung Sik Kim Department of Surgery, Severance Hospital, Yonsei University
More informationLog odds of positive lymph nodes is a novel prognostic indicator for advanced ESCC after surgical resection
Original Article Log odds of positive lymph nodes is a novel prognostic indicator for advanced ESCC after surgical resection Mingjian Yang 1,2, Hongdian Zhang 1,2, Zhao Ma 1,2, Lei Gong 1,2, Chuangui Chen
More informationRadical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patients
Original Article : oncologic outcome in 271 Chinese patients Zhi-Ling Zhang, Pei Dong, Yong-Hong Li, Zhuo-Wei Liu, Kai Yao, Hui Han, Zi-Ke Qin and Fang-Jian Zhou Abstract Few large scale studies have reported
More informationSignificance of Hepatectomy for AJCC/UICC T3 Hepatocellular Carcinoma
Significance of Hepatectomy for AJCC/UICC T3 Hepatocellular Carcinoma TOSHIYA OCHIAI 1,2, HIROMICHI ISHII 1, YUSUKE YAMAMOTO 2, RYO MORIMURA 2, HISASHI IKOMA 2 and EIGO OTSUJI 2 1 Department of Surgery,
More informationThe effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More informationTwo Rare Metachronous Metastases of Hepatocellular Carcinoma After Liver Transplantation
Int Surg 2013;98:432 436 DOI: 10.9738/INTSURG-D-13-00026.1 Case Report Two Rare Metachronous Metastases of Hepatocellular Carcinoma After Liver Transplantation Satoshi Shinya 1, Tomoaki Noritomi 1, Yasushi
More informationIntrahepatic Sarcomatoid Cholangiocarcinoma with Portal Vein Thrombosis: A Case Report 1
Intrahepatic Sarcomatoid Cholangiocarcinoma with Portal Vein Thrombosis: A Case Report 1 Jae-Hoon Lim, M.D., Jin Woong Kim, M.D., Suk Hee Heo, M.D., Yong Yeon Jeong, M.D., Heoung Keun Kang, M.D. A 53-year-old
More informationDiabetes mellitus may affect the long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after liver transplantation
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v22.i43.9571 World J Gastroenterol 2016 November 21; 22(43): 9571-9585 ISSN 1007-9327
More informationInterventional Radiology in Liver Cancer. Nakarin Inmutto MD
Interventional Radiology in Liver Cancer Nakarin Inmutto MD Liver cancer Primary liver cancer Hepatocellular carcinoma Cholangiocarcinoma Metastasis Interventional Radiologist Diagnosis Imaging US / CT
More informationProfessor Norbert Bräu
Sixth Annual BHIVA Conference for the Management of HIV/Hepatitis Co-Infection in collaboration with BASL and BVHG Professor Norbert Bräu James J Peters VA Medical Center, New York, USA COMPETING INTEREST
More informationThe authors have declared no conflicts of interest.
Diagnostic Accuracy of Magnetic Resonance Cholangiopancreatography Versus Endoscopic Retrograde Cholangiopancreatography Findings in the Postorthotopic Liver Transplant Population Authors: *Ashok Shiani,
More informationTakahito Nakagawa, MD, Toshiya Kamiyama, MD, Kazuaki Nakanishi, MD, Hideki Yokoo, MD, Hirofumi Kamachi, MD, Michiaki Matsushita, MD, Satoru Todo, MD
Pulmonary for metastases from hepatocellular carcinoma: Factors influencing prognosis Takahito Nakagawa, MD, Toshiya Kamiyama, MD, Kazuaki Nakanishi, MD, Hideki Yokoo, MD, Hirofumi Kamachi, MD, Michiaki
More informationABSTRACT. Shuisheng Zhang 1, Xiaozhun Huang 2, Yuan Tian 3, Saderbieke Aimaiti 1, Jianwei Zhang 1, Jiuda Zhao 4, Yingtai Chen 1 and Chengfeng Wang 1
Clinicopathologic characteristics, laboratory parameters, treatment protocols, and outcomes of pancreatic cancer: a retrospective cohort study of 1433 patients in China Shuisheng Zhang 1, Xiaozhun Huang
More informationOutcome after emergency surgery in patients with a free perforation caused by gastric cancer
experimental and therapeutic medicine 1: 199-203, 2010 199 Outcome after emergency surgery in patients with a free perforation caused by gastric cancer Hironori Tsujimoto 1, Shuichi Hiraki 1, Naoko Sakamoto
More informationAnalysis of the outcome of young age tongue squamous cell carcinoma
Jeon et al. Maxillofacial Plastic and Reconstructive Surgery (2017) 39:41 DOI 10.1186/s40902-017-0139-8 Maxillofacial Plastic and Reconstructive Surgery RESEARCH Open Access Analysis of the outcome of
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationPrognostic Role of Gastrectomy in Patients With Gastric Cancer With Positive Peritoneal Cytology
Int Surg 2014;99:830 834 DOI: 10.9738/INTSURG-D-14-00119.1 Prognostic Role of Gastrectomy in Patients With Gastric Cancer With Positive Peritoneal Cytology Okihide Suzuki, Minoru Fukuchi, Erito Mochiki,
More informationArterial blood supply of hepatocellular carcinoma is associated with efficacy of sorafenib therapy
Original Article Page 1 of 5 Arterial blood supply of hepatocellular carcinoma is associated with efficacy of sorafenib therapy Qian Zhu 1 *, Xianghua Zhang 2 *, Jing Li 2, Liang Huang 2, Jianjun Yan 2,
More informationAnalysis of Lymph Node Metastasis Correlation with Prognosis in Patients with T2 Gastric Cancer
Analysis of Lymph Node Metastasis Correlation with Prognosis in Patients with T2 Gastric Cancer Xiaowen Liu 1,2, Ziwen Long 1,2, Hong Cai 1,2, Hua Huang 1,2, Yingqiang Shi 1,2, Yanong Wang 1,2 * 1 Department
More informationPrognostic Value of Plasma D-dimer in Patients with Resectable Esophageal Squamous Cell Carcinoma in China
1663 Ivyspring International Publisher Research Paper Journal of Cancer 2016; 7(12): 1663-1667. doi: 10.7150/jca.15216 Prognostic Value of Plasma D-dimer in Patients with Resectable Esophageal Squamous
More informationSuccessful en bloc resection of recurrent hepatocellular carcinoma directly invading the abdominal wall: a case report
Li et al. Journal of Medical Case Reports 2015, 9:19 JOURNAL OF MEDICAL CASE REPORTS CASE REPORT Open Access Successful en bloc resection of recurrent hepatocellular carcinoma directly invading the abdominal
More informationLymph node ratio as a prognostic factor in stage III colon cancer
Lymph node ratio as a prognostic factor in stage III colon cancer Emad Sadaka, Alaa Maria and Mohamed El-Shebiney. Clinical Oncology department, Faculty of Medicine, Tanta University, Egypt alaamaria1@hotmail.com
More informationUnmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim
Unmet needs in intermediate HCC Korea University Guro Hospital Ji Hoon Kim BCLC HCC Stage 0 PST 0, Child Pugh A Stage A C PST 0 2, Child Pugh A B Stage D PST > 2, Child Pugh C Very early stage (0) 1 HCC
More informationAdvances in percutaneous ablation for hepatocellular carcinoma
Advances in percutaneous ablation for hepatocellular carcinoma P. Nahon1,2,3 1 Hepatology, Jean Verdier Hospital, APHP, Bondy, France 2 Paris 13 university, Sorbonne Paris Cité, UFRSMBH, Bobigny, France
More informationEndoscopic Ultrasonography Assessment for Ampullary and Bile Duct Malignancy
Diagnostic and Therapeutic Endoscopy, Vol. 3, pp. 35-40 Reprints available directly from the publisher Photocopying permitted by license only (C) 1996 OPA (Overseas Publishers Association) Amsterdam B.V.
More informationPANCREATECTOMY WITH MESENTERIC AND PORTAL VEIN RESECTION FOR BORDERLINE RESECTABLE PANCREATIC CANCER: MULTICENTER STUDY
PROPOSAL: PANCREATECTOMY WITH MESENTERIC AND PORTAL VEIN RESECTION FOR BORDERLINE RESECTABLE PANCREATIC CANCER: MULTICENTER STUDY Pancreatic carcinoma represents the fourth-leading cause of cancer-related
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationHEPATIC METASTASES. We can state 3 types of metastases depending on their treatment options:
HEPATIC METASTASES 1. Definition Metastasis means the spread of cancer. Cancerous cells can separate from the primary tumor and enter the bloodstream or the lymphatic system (the one that produces, stores,
More informationAlpha-Fetoprotein-L3 for Detection of Hepatocellular (Liver) Cancer. Original Policy Date
MP 2.04.35 Alpha-Fetoprotein-L3 for Detection of Hepatocellular (Liver) Cancer Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature
More informationProximal Bile Duct Cancer: Contemporary Management. William R. Jarnagin, MD, FACS
Proximal Bile Duct Cancer: Contemporary Management William R. Jarnagin, MD, FACS Biliary Tract Adenocarcinoma Spectrum of disease Intrahepatic (IHC) Hilar EH Gallbladder GB CBD Distal D PD Biliary Tract
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationComparison Between Primary Closure of Common Bile Duct and T- Tube Drainage After Open Choledocholithiasis: A Hospital Based Study
Original article: Comparison Between Primary Closure of Common Bile Duct and T- Tube Drainage After Open Choledocholithiasis: A Hospital Based Study Kali CharanBansal Principal Specialist (General surgery)
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationMacroscopic types of intrahepatic cholangiocarcinoma and the eighth edition of AJCC/UICC TNM staging system
/, 2017, Vol. 8, (No. 60), pp: 101165-101174 Macroscopic types of intrahepatic cholangiocarcinoma and the eighth edition of AJCC/UICC TNM staging system Ze-Wu Meng 1,2,*, Wei Pan 1,2, Hai-Jie Hong 1,2,
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationClinical Staging for Hepatocellular Carcinoma: Eastern Perspectives. Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan
Clinical Staging for Hepatocellular Carcinoma: Eastern Perspectives Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan Why is staging system important? Cancer stage can be
More information간암의다양한병기분류법 : 현재사용중인병기분류를중심으로. Kim, Beom Kyung
간암의다양한병기분류법 : 현재사용중인병기분류를중심으로 Kim, Beom Kyung Importance of staging system 환자의예후예측 적절한치료방법적용 ( 수술, 방사선, 항암..) 의료진간의 tumor burden 에대한적절한의사소통 향후연구및 clinical trial 시연구집단의성격에대한객관적기준제시 Requisites for good staging
More informationLong-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules
Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA
More informationPrognostic Factors of Cholangiocarcinoma After Surgical Resection: A Retrospective Study of 293 Patients
e-issn 1643-3750 DOI: 10.12659/MSM.893586 Received: 2015.01.16 Accepted: 2015.03.23 Published: 2015.08.13 Prognostic Factors of Cholangiocarcinoma After Surgical Resection: A Retrospective Study of 293
More informationCLINICAL LIVER, PANCREAS, AND BILIARY TRACT
GASTROENTEROLOGY 2008;134:1908 1916 BILIARY TRACT Neither Multiple Tumors Nor Portal Hypertension Are Surgical Contraindications for Hepatocellular Carcinoma TAKEAKI ISHIZAWA, KIYOSHI HASEGAWA, TAKU AOKI,
More informationRESEARCH ARTICLE. Abstract. Introduction
RESEARCH ARTICLE Clinicopathologic Characteristics and Prognoses for Multicentric Occurrence and Intrahepatic Metastasis in Synchronous Multinodular Hepatocellular Carcinoma Patients Shi-Lai Li 1, Ming
More informationAntiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy
Cancer Biol Med 2013;10:158-164. doi: 10.7497/j.issn.2095-3941.2013.03.006 ORIGINAL ARTICLE Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy Yang Ke*,
More informationHepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010
Bronx VA Medical Center Mount Sinai School of Medicine Hepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010 Norbert Bräu, MD, MBA Associate
More informationLiver Cancer And Tumours
Liver Cancer And Tumours What causes liver cancer? Many factors may play a role in the development of cancer. Because the liver filters blood from all parts of the body, cancer cells from elsewhere can
More information